Aequim Alternative Investments LP Biomarin Pharmaceutical Inc Transaction History

Aequim Alternative Investments LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $2.01 Million - $2.69 Million	22,900 Added 113.93%	43,000 $4.18 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $493,673 - $662,643	6,100 Added 43.57%	20,100 $2.08 Million
Q3 2021 Nov 04, 2021	BUY	$74.77 - $85.47 $209,356 - $239,316	2,800 Added 25.0%	14,000 $1.08 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $2.56 Million - $3.18 Million	-35,200 Reduced 75.86%	11,200 $982,000
Q4 2020 Feb 10, 2021	BUY	$72.61 - $90.2 $2.56 Million - $3.18 Million	35,200 Added 314.29%	46,400 $1.17 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $2.36 Million - $4.3 Million	-32,800 Reduced 74.55%	11,200 $852,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $1.57 Million - $2.13 Million	22,000 Added 100.0%	44,000 $3.72 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $741,400 - $936,210	11,000 Added 100.0%	22,000 $1.48 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $883,849 - $1.03 Million	11,000 New	11,000 $942,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Aequim Alternative Investments LP, based on Form 13F filings with the SEC.

Stay updated on Aequim Alternative Investments LP with notifications on news.